Payment overview · 2025
General Payments
$2,839.79
75 reported records · 15 companies
Healthcare provider profile · identity verified
Andrew Y Lin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUNNYVALE, CA · NPI 1679635254
Verified facts
What the public records show
CMS Open Payments records show Andrew Y Lin, MD received $2,839.79 in general payments during 2025 across 75 reported records.
Abbott Laboratories accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $677.07 | 23.8% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $530.84 | 18.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $330.51 | 11.6% | 13 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $300.16 | 10.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $266.95 | 9.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.86 | 6.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $145.29 | 5.1% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.99 | 4.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.69 | 2.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $62.48 | 2.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.61 | 1.8% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $42.35 | 1.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.90 | 1.0% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $17.95 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.14 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,839.79 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $391.94 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $330.51 | 13 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $300.16 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $270.91 | 11 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $268.56 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $254.44 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $153.95 | 3 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $139.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $126.91 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $126.91 | 5 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $120.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.02 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $113.51 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.50 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $70.69 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.84 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.78 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.90 | 1 | 2025 |
Source payment records
|
|||||
| AGILIS Normalized: agilis |
Device | Abbott Laboratories | $26.48 | 2 | 2025 |
Source payment records
|
|||||
| ADVISOR Normalized: advisor |
Device | Abbott Laboratories | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Abbott Laboratories | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1295 | 402 |
| Amlodipine Besylate | Amlodipine Besylate | 784 | 208 |
| Losartan Potassium | Losartan Potassium | 656 | 193 |
| Metformin Hcl | Metformin Hcl | 446 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 65 |
| Lisinopril | Lisinopril | 212 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 70 |
| Simvastatin | Simvastatin | 185 | 50 |
| Azithromycin | Azithromycin | 165 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 70 |
| Omeprazole | Omeprazole | 156 | 68 |
| Valsartan | Valsartan | 149 | 47 |
| Alendronate Sodium | Alendronate Sodium | 148 | 49 |
| Allopurinol | Allopurinol | 145 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 140 | 90 |
| Baclofen | Baclofen | 134 | 68 |
| Trazodone Hcl | Trazodone Hcl | 131 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 124 | 36 |
| Gabapentin | Gabapentin | 121 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 58 |
| Finasteride | Finasteride | 114 | 38 |
| Meloxicam | Meloxicam | 109 | 43 |
| Atenolol | Atenolol | 98 | 24 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Eliquis | Apixaban | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 26 |
| Famotidine | Famotidine | 84 | 30 |
| Furosemide | Furosemide | 79 | 29 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 34 |
| Montelukast Sodium | Montelukast Sodium | 72 | 29 |
| Carvedilol | Carvedilol | 68 | 24 |
| Donepezil Hcl | Donepezil Hcl | 68 | 16 |
| Mirtazapine | Mirtazapine | 68 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 30 |
| Jardiance | Empagliflozin | 57 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 51 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 49 | 48 |
| Ketoconazole | Ketoconazole | 47 | 23 |
| Amoxicillin | Amoxicillin | 46 | 31 |
| Glimepiride | Glimepiride | 46 | 16 |
| Hydrocortisone | Hydrocortisone | 46 | 25 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Ozempic | Semaglutide | 46 | 11 |
| Myrbetriq | Mirabegron | 44 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Glipizide | Glipizide | 37 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Ciclopirox | Ciclopirox | 34 | 18 |
| Mupirocin | Mupirocin | 33 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Cephalexin | Cephalexin | 30 | 25 |
| Fluocinonide | Fluocinonide | 30 | 23 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Prolia | Denosumab | 28 | 18 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Colchicine | Colchicine | 26 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 12 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 15 |
| Benzonatate | Benzonatate | 18 | 14 |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 12 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,839.79 · 75 records | Abbott Laboratories | ADVISOR, AGILIS, AIRSUPRA, AREXVY, ASSURITY, AVEIR, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ENSITE, EVENITY, FARXIGA, Flector, GALLANT, JARDIANCE, LEQVIO, Licart, NA, NEFFY, NEXLETOL, OTEZLA, Ozempic, PERCLOSE PROSTYLE, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tirosint, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error